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The Wnt/β-catenin pathway is an evolutionarily conserved signaling pathway critical for 
several biological processes. An aberrant Wnt/β-catenin signaling is linked to several 
human diseases. Emerging studies have highlighted the regulatory role of the Wnt/ 
β-catenin signaling pathway in normal physiological processes of parenchymal and 
hematopoietic cells. Recent studies have shown that the activation of Wnt/β-catenin 
pathway in dendritic cells (DCs) play a critical role in mucosal tolerance and suppres-
sion of chronic autoimmune pathologies. Alternatively, tumors activate Wnt/β-catenin 
pathway in DCs to induce immune tolerance and thereby evade antitumor immunity 
through suppression of effector T cell responses and promotion of regulatory T cell 
responses. Here, we review our work and current understanding of how Wnt/β-catenin 
signaling in DCs shapes the immune response in cancer and autoimmunity and discuss 
how Wnt/β-catenin pathway can be targeted for successful therapeutic interventions in 
various human diseases.
Keywords: immunotherapy, wnt, β-catenin, dendritic cells, immune-tolerance, immuno-oncology, autoimmune 
diseases, antitumor immunity
iNTRODUCTiON
The immune system functions constantly to defend from pathogens while preserving tolerance 
to self-antigens and commensal microbes (1, 2). Activation of the immune system in response to 
pathogens or sterile inflammation involves a cascade of innate and adaptive immune responses that 
are precisely controlled through a complex network of regulatory mechanisms (3, 4). Aberrations 
in immune-regulatory pathways result in different conditions including cancer and autoimmune 
diseases. The immune system is equipped with diverse cell types and secreted factors to achieve 
constant surveillance against pathogens while maintaining tolerance to self. Proinflammatory leu-
kocyte subsets, such as monocytes, NK cells, and cytotoxic T cells, mainly provide protection from 
pathogens and cancer, whereas various subsets of regulatory T cells check untoward inflammatory 
mechanisms. Unlike other leukocytes, dendritic cells (DCs) possess the ability to elicit both pro- 
and anti-inflammatory functions made possible by the presence of various regulatory mechanisms, 
including crosstalk between Toll-like receptor (TLR)- and Wnt/β-catenin signaling pathways.
2Suryawanshi et al. Regulating Wnt/β-Catenin Signaling in Dendritic Cells
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 460
Dendritic cells are crucial in the induction of immunity and 
tolerance. Every tissue in humans is armed with DCs to sense and 
induce inflammatory immune responses against pathogens or to 
preserve a tolerogenic environment under steady state conditions. 
DCs equipped with pattern-recognition receptors (PRRs) play a 
central role in detection of pathogen-associated molecular pat-
terns (PAMPs) and induction of robust host immunity through a 
controlled activation of different arms of the innate and adaptive 
immune responses (5, 6). DCs as professional antigen-presenting 
cells (APCs) recognize PAMPs through membrane-bound TLRs 
and C-type lectin receptors (CLRs) or cytoplasmic NOD-like 
receptors (NLRs) and RIG-1-like receptors (RLRs) (2, 3, 4).
Recognition of pathogens by DCs leads to phagocytosis 
of microbes, cytokine production, and expression of antigen 
presentation and costimulatory molecules, ultimately causing 
selective polarization of adaptive immune responses based 
on the type of pathogen. Accordingly, intracellular infections 
promote IFN-γ and IL-12 production by DCs that activates 
IFN-γ-producing CD4+ T helper 1 (Th1) and CD8+ cytotoxic 
T cell responses, whereas extracellular pathogens activate DCs 
to induce IL-4-producing CD4+ T helper 2 (Th2) cell responses 
(4, 7). Alternatively, DCs can induce IL-17A+CD4+ T helper 17 
(Th17) cell responses against fungi and extracellular bacteria 
through increased production of IL-6, TGF-β, and IL-23 (3, 4, 8).
In addition to induction of immunity against pathogens, DCs 
contain effector immune responses and maintain peripheral tol-
erance to self-antigens, commensal microorganisms, and dietary 
components (2, 6). DCs generate tolerance and control chronic 
inflammatory responses by various mechanisms, including 
induction of anergic or regulatory T cell responses, and regulat-
ing effector Th1, Th2, and Th17 cell responses through differential 
expression of costimulatory molecules and secretion of regulatory 
cytokines (2, 6). Although significant progress has been achieved 
in our understanding on DCs’ diverse mechanisms in eliciting 
effector T cell responses in immunity, the signaling networks that 
program DCs into a regulatory state are poorly defined. In this 
regard, recent studies have discovered the critical functions of the 
Wnt/β-catenin signaling pathway of DCs in regulation of immune 
responses in various pathological conditions. Here, we review our 
current understanding and significance of Wnt/β-catenin signal-
ing in DCs in the induction of immune tolerance in physiological 
conditions, autoimmuninty, and oncogenesis.
wnt/β-CATeNiN SiGNALiNG
Wnt/β-catenin signaling plays a critical role in cell differentia-
tion, growth, proliferation, survival, and immune cell function 
(9, 10). Wnts are secreted lipid-modified glycoproteins that bind 
to seven-pass transmembrane Frizzled (Fzd) family receptors and 
activate multiple signaling pathways. In humans, there are 19 Wnt 
proteins and 10 cognate Fzd receptors (10, 11). The binding of 
Wnts to Fzd receptors activates canonical and/or non-canonical 
signaling pathways (Figure 1) (9, 10, 12). Low-density lipopro-
tein receptor-related protein 5 (LRP5) and LRP6 co-receptors 
are essential for optimal activation of canonical Wnt/β-catenin 
signaling (10, 13, 14). Wnt interaction with Fzd receptors results 
in cytoplasmic accumulation of β-catenin and its translocation 
into the nucleus, where it interacts with T-cell factor/lymphoid 
enhancer factor (TCF/LEF) and regulates the transcription of 
several target genes (9, 12). Wnt ligands also can stimulate other 
non-canonical signaling pathways independent of β-catenin 
activation (11).
In the absence of Wnt and Fzd interaction, β-catenin actively 
synthesized in the cytoplasm is removed through a destruction 
complex (9, 10, 14). This destruction complex consists of scaffold-
ing proteins, such as axin and adenomatous polyposis coli (APC), 
and Ser/Thr kinases such as casein kinase 1α (CK1α) and glycogen 
synthase kinase 3β (GSK3β) (9, 10, 13). GSK-3β phosphorylates 
β-catenin, leading to ubiquitination and proteasomal degradation 
mediated by β-transducin repeat-containing (β-TrCP) protein 
and Wilms tumor suppressor protein complex (Wtx) (9–11). Wnt 
binding of the Fzd receptor leads to recruitment of co-receptors 
LRP5/6 and is followed by recruitment of disheveled (DVL) to 
the cytoplasmic tail of LRP5/6 (9, 10, 11, 13). These signaling 
events inactivate the destruction complex by recruiting it to the 
plasma membrane. Moreover, GSK3β in the destruction complex 
phosphorylates LRP5/6 instead of β-catenin, leading to increased 
accumulation of β-catenin in the cytoplasm (9, 10, 11, 13).
Thus, Wnts activate β-catenin signaling through inhibition 
of β-catenin destruction, resulting in its cytoplasmic accumula-
tion and translocation to the nucleus. In the nucleus, β-catenin 
displaces the co-repressor molecule Groucho from the TCF/LEF 
complex and activates transcription of target genes (9, 10, 11, 13).
wnt-iNDePeNDeNT β-CATeNiN 
SiGNALiNG iN DCs
e-Cadherin in β-Catenin Activation
In addition to Wnt-mediated activation of β-catenin, there are 
numerous pathways that function independent of Wnt ligands 
involved in activation of β-catenin in DCs (Figure 2). For exam-
ple, disruption of E-cadherin–homophilic interactions in DCs 
activates β-catenin, which in turn programs DCs to a regulatory 
state (15). Importantly, these regulatory DCs produce high levels 
of IL-10 in response to LPS and protect mice from experimental 
autoimmune encephalomyelitis (EAE) (15). The cytoplasmic 
domain of E-cadherin is known to interact with and sequester 
β-catenin (16). This would therefore limit β-catenin signaling in a 
manner independent of Wnt ligands or axin destruction complex 
expression. E-cadherin-mediated disruption of β-catenin signal-
ing is further supported by observations of phosphorylation and 
degradation of β-catenin by destruction complexes localized pri-
marily at adherens junctions (17). This suggests a significant link 
between E-cadherin interactions and canonical Wnt signaling.
Additional binding factors also may mediate this function 
of E-cadherins at adherens junctions. Caveolin-1, for example, 
may be recruited by E-cadherin in order to support inhibition of 
β-catenin signaling (18). In a recent study, casein kinase 1 (CK1) 
was shown to phosphorylate another E-cadherin-associated 
protein known as p120-catenin, which in response to Wnt3a 
binding stabilizes E-cadherin interactions (19). This subse-
quently aids in recruitment of CK1 to the LRP5/6 co-receptor 
for canonical Wnt signaling pathway activation (19). In addition, 
FiGURe 1 | The wnt/β-catenin signaling pathway. In the absence of Wnt ligands, β-catenin levels in the cytoplasm are largely reduced by the following means: 
(1) a destruction complex consisting of the scaffolding proteins APC and AXIN, as well as Ser/Thr kinases CK1α and GSK3β, interacts with β-catenin in the cytosol 
to induce phospho-inactivation of the protein by the two Ser/Thr kinases. (2 and 3) Phospho-β-catenin is promoted to ubiquitination and subsequent proteasomal 
degradation by β-Trcp and WTX proteins. In contrast, in the presence of Wnt ligands, β-catenin levels in the cytoplasm are upregulated and actively participate in cell 
signaling through the following steps: (1) Wnts bind to cognate Fzd receptors and interact with adjacent LRP5/6 co-receptors, (2) the resulting complex recruits DVL 
to the cytoplasmic tail of Fzd receptors, and (3) DVL recruits the destruction complex to the Fzd/LRP5/6 complex and associated Ser/Thr kinases such as GSK3β 
phosphorylate the co-receptor instead of β-catenin due to the altered localization of the complex. Moreover, cytoplasmic TNKS ubiquitinates Axin, targeting it for 
proteasomal degradation and causing disruption of the β-catenin destruction complex. (4) Cytosolic β-catenin levels are free to accumulate and subsequently 
translocate to the nucleus. (5) This translocation results in the displacement of the co-repressor Groucho on the TCF/LEF transcription factor by β-catenin and the 
recruitment of co-activators such as BCL9, CBP, and PYGO to result in the transcription of target genes. Alternate means of activation of β-catenin signaling include 
the disruption of epithelial cadherin (E-cadherin)–E-cadherin interactions, which frees the association of β-catenin to the cytoplasmic domain of E-cadherin and 
allows for its accumulation in the cytoplasm. In addition, TLRs and other such transmembrane receptors may result in PI3K/Akt signaling. This leads to an alternative 
phospho-activation of β-catenin through phosphorylation at Ser552 and phospho-inactivation of GSK3β at Ser9 to prevent the degradation of β-catenin by the 
destruction complex and allow it to accumulate in the cytoplasm and participate in cell signaling. Abbreviations: APC, adenomatous polyposis coli; CK1α, casein 
kinase 1α; GSK3β, glycogen synthase kinase 3β; WTX, Wilms tumor suppressor protein complex; β-Trcp, β-transducin repeat-containing protein; TNKS, 
tankyrase-1; Fzd, Frizzled; LRP5/6, low-density lipoprotein receptor-related protein 5/6; DVL, disheveled; TCF/LEF, T-cell factor/lymphoid enhancer factor; BCL9, 
B-cell CLL/lymphoma 9 protein; CBP, CREB-binding protein; PYGO, Pygopus; TLR, Toll-like receptor; PI3K, phosphoinositide-3-kinase.
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CK1 phosphorylation of E-cadherin weakens its affinity for 
β-catenin, thus increasing free β-catenin levels in the cytosol for 
signaling. Elimination of p120-catenin inhibited Wnt-mediated 
β-catenin signaling. Unligated E-cadherin may therefore support 
β-catenin signaling by helping canonical Wnt signaling in cells. 
This indicates that the extent of cell–cell interactions mediated 
by E-cadherins does play a significant role in immunity and 
tolerance.
TLRs in β-Catenin Activation
Activation of TLRs is known to modulate β-catenin signaling in 
different immune and non-immune cells (20). In this regard, a 
recent study has shown that TLR2 signaling through the PI3K/Akt 
pathway activates β-catenin in DCs and induces the expression 
of vitamin A-metabolizing enzymes and IL-10 (Figure 2) (21). 
Interestingly, activation of TLR2 in DCs promotes T regula-
tory cell responses and protects mice from Th1/Th17-mediated 
autoimmune neuroinflammation (21, 22). Stimulation of TLR2 
present on DCs increased IL-10 production through increased 
expression and phosphorylation of extracellular signal-regulated 
kinase (ERK) and mitogen-associated protein kinase (MAPK) 
(23, 24). Phosphorylation of β-catenin at Ser552 by Akt activates 
its nuclear transcription activity, whereas Akt phosphorylation of 
GSK3β at Ser9 prevents it from marking β-catenin for degrada-
tion (25, 26, 27). Inhibition of the Akt or Erk pathway individually 
in DCs showed that β-catenin signaling via TLR2 stimulation is 
primarily dependent on Akt but not Erk (21). This shows that 
β-catenin signaling works synergistically with other pathways, 
FiGURe 2 | β-catenin signaling in DCs induces immune tolerance. β-catenin upregulation is induced in dendritic cells via a number of different receptor 
interactions, including canonical Wnt/Fzd signaling, stimulation of TLRs such as TLR2 with antigen and subsequent ERK signaling, Fas receptor activation, release 
of β-catenin from E-cadherins upon disruption of E-cadherin interactions, or activation of other pattern-recognition receptors such as Fcγ receptors or dectin-1. This 
results in β-catenin-mediated association of the TCF/LEF transcription factor with various co-activators that lead to transcription of target genes. This further results 
in the expression of anti-inflammatory cytokines, such as IL-10 and IL-27, which induce type 1 regulatory T (Tr1) cells or CD8+IL-10+ T cells, and TGF-β, which 
induces FoxP3+ regulatory T (Treg) cells. In addition, β-catenin signaling in DCs upregulate vitamin A-metabolizing enzymes (RALDH 1/2), which convert vitamin A to 
retinoic acid (RA). RA induces Treg differentiation. Accumulation of Tregs in the tissue microenvironment may result in inhibition of proinflammatory Th1/Th17 cells or 
CD8+ cytotoxic T cells. Pharmacological inhibition of β-catenin signaling components may thus lead to downregulation of regulatory T cells to mount a more robust 
effector T cell response against chronic infections and tumors, which may utilize β-catenin signaling components to engage in immune surveillance evasion. Such 
inhibitors include TNKS inhibitors, XAV939 and JW55, and PORCN inhibitor, C59. In contrast, pharmacological activation of β-catenin signaling components may 
result in upregulation of regulatory T cells to dampen chronic inflammation and autoimmunity. Such activators include the Axin/β-catenin interaction disruptor 
SKL2001 and administration of canonical Wnts. Abbreviations: Fzd, Frizzled; TLR, Toll-like receptor; ERK, extracellular signal-related kinase; Muc, mucin; Gal3, 
galectin 3; TCF/LEF, T cell factor/lymphoid enhancer factor; IL-10, interleukin 10; IL-27, interleukin 27; FoxP3, forkhead box P3; TGFβ, transforming growth factor β; 
RALDH 1/2, retinaldehyde dehydrogenase 1/2; Th1/17 cells, T helper 1/17 cells; TNKS, tankyrase-1; PORCN, porcupine.
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such as the Erk pathway, to induce anti-inflammatory cytokines 
and proliferation of T regulatory cells. Like TLR2, other TLRs 
such as TLR3, TLR5, and TLR9 are known to activate or regulate 
β-catenin signaling via a mechanism dependent on PI3K/AKT 
and Erk pathways (20, 21, 28).
In addition to E-cadherin and TLR stimulation, other path-
ways such as FAS (29), TGF-β (30), and PLC-γ2 (31) activate 
or regulate β-catenin signaling in DCs. Further studies are war-
ranted to elucidate how these pathways may work in tandem to 
effectively establish a tolerogenic phenotype in DCs.
wnt/β-CATeNiN SiGNALiNG OF DCs iN 
THe ReGULATiON OF TOLeRANCe AND 
iNFLAMMATiON
Although activation of effective innate and adaptive immune 
responses is critical for protective immunity, uncontrolled activa-
tion of these immune responses results in chronic autoimmune 
and inflammatory conditions. Moreover, induction of adaptive 
immunity against commensal microorganisms at mucosal sites, 
self-antigens, and food constituents is detrimental to human health 
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(1, 2, 6). In this context, DCs play an important role in inducing 
peripheral immune tolerance at mucosal surfaces through several 
regulatory mechanisms (1, 2, 4, 6). Furthermore, DCs contribute 
to the resolution of inflammation through inhibition of ongo-
ing effector T cell responses and induction of regulatory T cell 
responses. Although past studies have characterized the role of 
Wnt/β-catenin signaling in hematopoiesis, cell differentiation, 
proliferation, and homeostasis, the role of this pathway in DCs 
in regulating immune responses is poorly understood. Recently, 
several studies from others and our lab have begun to explore 
the function of this regulatory pathway in inducing immune 
tolerance and its significance during cancer, autoimmunity, and 
infectious diseases (Figure 2). In the next few sections, we will 
review recent developments in our understanding of the role 
of Wnt/β-catenin signaling in regulating immune responses in 
pathological conditions.
wnt/β-CATeNiN SiGNALiNG iN DCs 
ReGULATeS MUCOSAL TOLeRANCe
Mucosal tolerance to commensals and food antigens is required 
for optimum health. Mucosal DCs play an important role in 
inducing peripheral tolerance. Gut DCs are in constant contact 
with microbial and food antigens and exhibit impaired immune-
stimulatory capacity (2, 4, 6). Wnt/β-catenin signaling is essential 
for intestinal homeostasis including epithelial cell proliferation 
and maintenance of stem cells (32–36). Studies have shown that 
aberrant activation of the Wnt/β-catenin pathway in intestinal 
epithelial cells results in uncontrolled proliferation, polyps forma-
tion, and the development of colorectal cancer (33, 35, 37, 38, 39). 
Under homeostasis, the intestine expresses several components 
of the Wnt/β-catenin signaling pathway, including different Wnt 
ligands, Fzd receptors, and LRP5/6 co-receptors (40).
Although several studies have shown the importance of 
Wnt/β-catenin signaling in the maintenance of intestinal epithe-
lial cell homeostasis, the role of this pathway in inducing immune 
tolerance is poorly defined. In this regard, a recent study showed 
that β-catenin is constitutively active in intestinal DCs and mac-
rophages compared to splenic DCs (41). This study demonstrated 
that expression of β-catenin in intestinal DCs is critical for the 
induction of regulatory T cell responses and suppression of Th1 
and Th17 cell responses. Thus, DC-specific deletion of β-catenin 
results in increased Th1 and Th17 cells over T regulatory cells in 
the intestine but not in the spleen (41). Interestingly, the absence 
of β-catenin in DCs shifts the balance from anti-inflammatory 
cytokine production to increased production of proinflamma-
tory cytokines in the intestine, suggesting a tolerogenic role of 
β-catenin signaling in gut DCs (41). Moreover, a recent study 
showed that MUC2, a gel-forming mucin secreted by intestinal 
goblet cells, mediates mucosal tolerance in the intestine through 
activation of β-catenin signaling in DCs (42). This study showed 
that MUC2 is readily taken in by small intestinal DCs through 
interaction with Galectin-3, dectin-1, and FcγRIIB. This activates 
β-catenin in DCs to induce mucosal tolerance against intestinal 
commensal microorganisms. Thus, MUC2-mediated activation 
of β-catenin in small intestinal DCs suppressed inflammatory 
immune responses through suppression of the NF-κB pathway 
(42). These studies indicate the vital role of β-catenin signaling 
not only in epithelial cell homeostasis but also in the maintenance 
of gut tolerance through regulatory effects of DCs. Further 
studies on the role of commensal-derived factors, Wnt ligands, 
mucosal proteins, and various dietary ligands on activation of 
this pathway will identify novel regulatory mechanisms by which 
a normal intestine maintains tolerance. These studies will also 
help in designing better DC-based immunotherapy treatment 
approaches for enteric pathogens as well as chronic inflammatory 
conditions of the gut.
wnt/β-CATeNiN SiGNALiNG iN DCs:  
A POTeNTiAL THeRAPeUTiC TARGeT 
FOR CHRONiC iNFLAMMATiON
Although mucosal tolerance is actively enforced all the time 
to achieve optimum health, dysregulation of the host immune 
system and commensal microflora results in the development of 
inflammatory bowel diseases (IBDs) such as ulcerative colitis and 
Crohn’s disease (43). In IBD, intestinal DCs and macrophages lose 
their tolerogenic properties, resulting in uncontrolled intestinal 
inflammation (43). Accordingly, our recent study showed that 
mice lacking β-catenin in DCs are more susceptible to dextran 
sodium sulfate (DSS)-induced colitis, a mouse model for IBD, 
compared to β-catenin-sufficient mice, indicating the critical 
role of this pathway in regulation of inflammatory diseases (41). 
DC-specific deletion of β-catenin in mice led to increased body 
weight loss in response to DSS treatment with severe colonic epi-
thelial layer destruction and increased Th1 and Th17 cell responses 
(41). Although this study identified the immune-regulatory role 
of β-catenin in DCs in inducing mucosal tolerance and protection 
against IBD, further studies are warranted to determine upstream 
and downstream signaling components for β-catenin activation 
in intestinal DCs.
Multiple sclerosis (MS) is a chronic autoimmune neuroinflam-
matory disease that leads to multifocal demyelination in the white 
matter of the human CNS with debilitating motor and sensory 
dysfunction (44, 45). Previous studies using EAE, a mouse model 
for MS, have shown that DCs play a critical role in initiation and 
development of CNS pathology through activation of effector 
T cells in the draining lymph nodes (DLN) and CNS (44, 45). 
These studies have shown that DCs contribute to CNS pathology 
through differentiation and activation of naive CD4+ T cells to 
myelin-specific effector Th1 and Th17 cells (44, 46). Furthermore, 
studies have also indicated the critical role of CD8+ T cells in 
causing EAE and MS pathogenesis (47, 48). Although the role of 
DCs in initiating effector T cell responses during EAE and MS 
is well characterized, emerging evidence indicates that DCs are 
also critical in resolving inflammation and in limiting immune-
mediated pathology in EAE. DCs play a regulatory role through 
production of immune-regulatory factors, T regulatory cell acti-
vation, and fine-tuning of effector Th1 and Th17 cell responses 
(2, 4, 6). However, the molecular signaling networks and counter-
regulatory mechanisms that induce these regulatory responses 
are poorly defined. Particularly, the immune modulatory factors 
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in the local DLN and tissue microenvironment that are critical in 
programing DCs to induce tolerance during EAE and MS remain 
to be understood.
Recent studies from our laboratory have identified the 
critical function of Wnt/β-catenin signaling and the role of 
TLR2-mediated activation of β-catenin in regulating ongoing 
effector immune responses and CNS pathology (21, 49). Our data 
suggest that excessive neuroinflammation is controlled through 
increased Wnt ligand expression as a feedback mechanism to 
counter ongoing inflammatory responses. Thus, Wnt3a and 
Wnt5a expression is significantly upregulated in the DLN dur-
ing the EAE induction phase and in the CNS during the effector 
phase. Interestingly, previous studies have shown that the dys-
regulated Wnt signaling leads to neurodegenerative and inflam-
matory disorders (50). Furthermore, it has been reported that 
sustained activation of the Wnt pathway restrains inflammation, 
stimulates neuroprotection, and promotes neurogeneration (49, 
50). However, the role of Wnt/β-catenin in specific cell types has 
not been identified during ongoing EAE pathology. Results from 
our study show that DC-specific deletion of LRP5/6 or β-catenin 
leads to early onset as well as increased EAE pathology, indicating 
the critical role of canonical Wnt-mediated β-catenin activation 
in DCs in limiting CNS pathology (21, 49). Mechanistically, the 
absence of Wnt/β-catenin signaling in DCs lead to an increased 
proinflammatory cytokine production in the DLN and CNS, as 
well as increased effector Th1, Th17, and CD8+ T cell responses 
and diminished production of anti-inflammatory cytokines such 
as IL-10, TGF-β, and IL-27 (49). Furthermore, transgenic mice 
with a constitutively active form of β-catenin in DCs showed 
diminished neuroinflammation with reduced effector and 
increased regulatory T cell responses confirming the regulatory 
role of β-catenin signaling in DCs. Moreover, prophylactic and 
therapeutic treatment with β-catenin agonists in EAE-induced 
mice showed diminished EAE pathology, suggesting that immu-
notherapies targeting Wnt/β-catenin signaling specifically in DCs 
could represent a promising therapeutic approach for clinical 
management of MS.
Interestingly, Wnt5a, which signals independently of the 
β-catenin pathway, also reprograms DCs to limit the expression 
of inflammatory cytokines (51, 52). It is possible that both the 
canonical and non-canonical pathways might act in concert to 
regulate the level of inflammation. In addition to direct Wnt-
mediated activation of β-catenin and other regulatory pathways, 
TLR2-mediated signals also induce active β-catenin in DCs and 
regulate EAE pathology (21). This study showed that TLR-2-
mediated activation of β-catenin in DCs promotes IL-10 and 
retinoic acid (RA) production, which in turn promotes regula-
tory T cell responses and suppresses effector T cell responses. 
Furthermore, E-cadherin-mediated signaling can also activate 
β-catenin in DCs, suppressing chronic inflammation and EAE 
disease severity (15, 21). In addition to DCs, macrophages and 
microglial cells also play a critical role in initiation and resolu-
tion of EAE pathogenesis (53, 54). Although these observations 
indicated the role for Wnts and TLRs in modulating DC activity 
during EAE, it is quite possible that increased Wnt ligand expres-
sion could regulate functions of macrophage and microglial cells 
and limit EAE pathology. Further studies on cellular source and 
targets of Wnt ligands during different stages of EAE are neces-
sary to delineate the regulatory role of the Wnt/β-catenin pathway 
during autoimmune neuroinflammation.
Several recent studies have characterized the critical role of 
Wnt/β-catenin signaling in the pathogenesis of chronic inflam-
matory diseases such as lupus, psoriasis, and rheumatoid arthritis. 
For example, using murine models for lupus, it has been shown 
that Dickkopf-1 (DKK1), a negative regulator of the Wnt/β-
catenin pathway, is highly upregulated in the serum during lupus 
progression (55). Similarly, serum samples from lupus patients 
showed increased levels of DKK1, suggesting altered canonical 
Wnt signaling in the development of lupus (56). DKK1 overex-
pression has also been observed in humans in other autoimmune 
disorders. For example, skin and peripheral blood mononuclear 
cells expressed increased levels of the Wnt signaling inhibitor in 
psoriasis (57). However, it is not known whether increases in the 
levels of negative regulators of the Wnt pathway alter functions 
of DCs or macrophages.
In contrast to negative regulators of the canonical Wnt-
pathway, aberrant expression of Wnts such as Wnt5a and Wnt7B 
that activate the non-canonical pathway was observed in the 
joints of rheumatoid arthritis patients (58). Conversely, effects 
of these Wnts on immune cell function are not known. Recent 
studies also imply downregulation of canonical Wnt signaling 
receptors in rheumatoid arthritis, as indicated by silencing of Fzd8 
by miRNA-375 in arthritis synovial fibroblasts (59). Activation 
of Wnt signaling in rheumatoid arthritis has been known to 
induce proliferation of fibroblast-like synoviocytes and increases 
in synovial inflammation (58). Also, non-canonical pathways 
may antagonize the canonical β-catenin signaling pathway by 
downregulating β-catenin protein expression (60, 61). Thus, 
it appears that upregulation of non-canonical Wnt signaling 
that leads to downregulation of canonical Wnt signaling may 
be occurring in rheumatoid arthritis to induce high levels of 
synovial inflammation. Wnt signaling has been known to play 
a role in cell renewal and keratinocyte differentiation, and the 
Wnt/Ca2+ non-canonical pathway has been correlated with the 
pathophysiology of psoriasis (62). The overexpression of Wnt5A 
and Fzd5 in psoriasis may denote the targeting of non-canonical 
Wnt pathway elements as an efficacious tactic in the remediation 
of psoriatic symptoms. Thus, activating the canonical Wnt/β-
catenin pathway and suppressing non-canonical Wnt signaling 
represent a potential therapeutic approach toward suppressing 
inflammation and limiting immune-mediated pathology.
wnt/β-CATeNiN SiGNALiNG iN DCs 
MODULATeS ANTiTUMOR iMMUNiTY
Although activation of β-catenin signaling in DCs is critical 
for mucosal tolerance and resolving chronic inflammatory 
conditions, tumor cells, and some pathogenic microbes exploit 
this pathway to effectively suppress DC-mediated host immune 
responses (20, 21, 63). Tumors use different mechanisms to 
evade immunity, including suppressing DC-induced antitumor 
immune responses in the tumor microenvironment (TME) (64, 
65). Numerous studies have shown increased Wnt expression in 
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tumors and linked dysregulation of the Wnt pathway with tumor 
progression (66). However, most studies focused on how the Wnt 
signaling cascade regulates tumor development, progression, 
and metastasis (67–70). The role of Wnt/β-catenin signaling in 
immune cells in the TME and its effect on host antitumor immu-
nity and tumor-induced immune tolerance remain unknown. 
Recent studies from several labs have shown that increased levels 
of Wnts in the TME can initiate paracrine signaling and modulate 
host antitumor immunity (63, 71–75).
Using different murine tumor models, we have shown that 
increased Wnt ligands in tumors program DCs to produce RA 
and IL-10, which promotes immune suppression by inducing 
regulatory T cell responses (63). Mechanistically, this is also 
due to activation of β-catenin signaling in TME DCs and their 
ability to up regulate immune-regulatory factors such as IDO, 
IL-10, and Raldh (63, 71, 73, 75). Furthermore, TME DCs 
express high levels of IL-10 and TGF-β that promotes immune 
tolerance through induction of IL-10-producing CD4+ and 
CD8+ T cells (63). Interestingly, IL-10 production by TME DCs 
is dependent on the β-catenin/TCF4 signaling axis (63, 71, 75, 
76) and mTOR/β-catenin signaling pathway (71). These studies 
further suggest that Wnt-mediated activation of β-catenin in 
TME DCs is critical for inducing tumor tolerance. Accordingly, 
conditional deletion of β-catenin or LRP5/6 in DCs markedly 
reduces regulatory T cell responses with increased effector CD8 
T cell responses, leading to suppression of tumor growth (63, 
75). Furthermore, blocking Wnt interaction with LRP5/6 and 
Fzd using small molecule inhibitors in tumor-bearing mice 
showed increased capture of tumor-associated antigen by DCs. 
This led to increased cross-priming of CD8 T cells and resulted 
in reduced tumor burden. Interestingly, recent study showed that 
melanoma-intrinsic β-catenin signaling suppresses antitumor 
immunity by regulating DC migration (74).
In addition, the TME also programs DC function by regulat-
ing its activation and maturation through diverse mechanisms, 
including expression of costimulatory (CD80, CD86, and CD40) 
and co-inhibitory (PD-L1 and PD-L2) molecules (64). Our 
data show that deletion of β-catenin in DCs results in increased 
activation of DCs in the TME with increased surface expression 
of costimulatory molecules and decreased expression of co-
inhibitory molecules (63). In addition to inducing regulatory T 
cells, β-catenin activation in DCs can also affect cross-priming of 
CD8+ T cell responses against tumors (71, 75). Though β-catenin 
is known to suppress DC activation and cross-priming (77), it 
remains to be determined whether β-catenin directly regulates 
DC activation or does so indirectly via RA and IL-10 (63).
Since Wnt-mediated activation of β-catenin in the TME 
promotes tumor progression through multiple mechanisms, 
pharmacological suppression of the β-catenin pathway repre-
sents a promising target for effective antitumor immunotherapy. 
Accordingly, treatment of mice with inhibitors that blocks the 
β-catenin/TCF pathway results in delayed tumor growth through 
suppression of regulatory T cell responses and increased antitu-
mor CD4 and CD8 T cell responses (63, 71–73, 75). Collectively, 
these observations suggest that Wnt family of ligands in the TME 
can initiate tumor-intrinsic β-catenin signaling and DC-intrinsic 
β-catenin signaling, and both contributing to immune 
suppression through different effector mechanisms. Blocking the 
Wnt/β-catenin pathway could represent a promising therapeutic 
approach toward breaking tumor-mediated immune suppression 
and augmenting antitumor immunity.
ReGULATiON OF wnt/β-CATeNiN 
SiGNALiNG iN DCs: NOveL TARGeTS  
FOR iMMUNOTHeRAPieS
The Wnt/β-catenin pathway in DCs is a key player in the 
pathogenesis of a wide amalgam of inflammatory and infectious 
diseases (10). Wnt/β-catenin pathway thus serves as a potential 
therapeutic target where activation results in the suppression 
of inflammatory pathologies, and suppression is beneficial in 
augmenting antitumor immunity (Figure 2) (21, 49, 63, 71–73, 
75). Small molecules that modulate the Wnt/β-catenin pathway 
have been extensively researched for use against various patho-
logical conditions (70, 78) (Figure  3). In this regard, a recent 
study of ours has shown that pharmacological activation of 
canonical Wnt/β-catenin signaling is beneficial in reducing EAE 
and associated CNS pathology (49). Mechanistic investigations 
about various pathways related to Wnt signaling have provided 
additional therapeutic targets for activation or suppression of 
canonical Wnt signaling in diseases (Figure 3). In addition to 
direct inhibition or activation of the canonical Wnt pathway, 
suppression of non-canonical Notch signaling, which can antag-
onize canonical Wnt signaling, may be beneficial in regressing 
symptoms of autoimmune disease. Non-canonical Wnt ligands 
Wnt5a and Wnt7b were upregulated in the joints of rheumatoid 
arthritis patients, and the non-canonical Wnt/Ca2+ pathway has 
been associated with the pathophysiology of psoriasis (58, 62). 
Pharmacological inhibition of Wnt5A, for example, may remedi-
ate inflammation and other symptoms in arthritis or psoriasis 
patients.
Optimal functioning of Wnt/β-catenin pathway in different 
type of non-immune and immune cells including DCs is vital 
for a range of cellular functions and homeostasis. Consequently, 
targeting Wnt/β-catenin pathway specifically in DCs and par-
ticularly in those DCs, which play a central role in the induction 
of autoimmune pathology or tumor progression is critical for 
successful therapeutic intervention to minimize off-target side 
effects. Therefore, it is crucial to understand the biology of dif-
ferent subsets of DCs and how Wnt/β-catenin pathway in these 
DCs subsets contributes to normal health and immunopathology. 
Moreover, further studies on understanding the biology Wnt/β-
catenin signaling in other immune cells such as B cells, CD8+ T 
cells and different subsets of CD4+ T cells are warranted for better 
therapeutic targeting of this pathway in autoimmunity and can-
cer. In this regard, recent advances in targeted delivery of small 
molecules and biologics represent a novel therapeutic approach to 
deliver Wnt/β-catenin signaling modulator specifically to DCs for 
clinical management of autoimmunity and cancer. Additionally, 
combining DCs-specific Wnt/β-catenin pathway inhibition 
with recent successful therapies targeting immune checkpoints 
represents a promising approach to promote antitumor immune 
responses.
FiGURe 3 | Potential wnt/β-catenin signaling therapeutic targets. Inhibition of the canonical Wnt/β-catenin pathway may occur via targeting a number of the 
pathway’s elements. Wnt ligand antagonists include SFRP, WIF, or mAbs generated against the ligands. Frizzled receptor interaction inhibition may occur through 
the administration of Fzd mAbs as well. DKK1 has been shown to elicit inhibition of LRP co-receptor function. Disheveled (DVL) interactions with Wnt signaling 
receptors may also be inhibited via FJ9, Bio 3289-8625, or NSC668036. Downstream inhibition may occur through inhibition of β-catenin and TCF/LEF interactions 
by a number of different inhibitors. Other Wnt signaling-activating components that may be inhibited include TNKS, an inhibitor of axin stability, and PORCN, a 
stimulator of Wnt secretion. Inhibition of this pathway may also be the result of the presence of activators of elements that regulate the functions of this pathway that 
induce the upregulation or increase in function of these regulatory elements. Such activators include those targeting the Ser/Thr kinases CK1α (IC261 and pyrvinium) 
and GSK3β (lithium, CT99021, and BIO), the axin scaffolding protein (SKL2000), or β-Trcp (Δ2G, STG28). Abbreviations: SFRP, secreted frizzled-related protein-1; 
WIF, Wnt inhibitory protein; Fzd, Frizzled; mAbs, monoclonal antibodies; DKK1, Dickkopf-related protein 1; LRP, low-density lipoprotein receptor-related protein; 
TCF/LEF, T cell factor/lymphoid enhancer factor; TNKS, tankyrase 1; PORCN, porcupine; CK1α, casein kinase 1α; GSK3β, glycogen synthase kinase 3β; β-Trcp, 
β-transducin repeat-containing protein.
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SUMMARY
The normal immune system functions by instigating an effective 
immune response against infectious agents while promoting 
tolerance toward commensal microbiota and self-antigens. The 
Wnt/β-catenin pathway participates in this balance through 
diverse mechanisms including the generation of tolerogenic 
DCs to regulate inflammatory responses. Inadequacies in the 
signaling of the Wnt/β-catenin pathway may result in allergic and 
autoimmune diseases through chronic and uncontrolled activa-
tion of the immune system or cancer due to inadequate immune 
surveillance resulting from excessive immune tolerance. Thus, 
Wnt/β-catenin signaling serves as a molecular switch between 
opposing immune functions, and targeting different elements of 
this pathway may provide therapeutic benefits in the remediation 
of autoimmune diseases, cancer, and infectious diseases. While it 
is clear that Wnt-signaling programs DCs to induce robust regu-
latory T cell responses and cytokines to contain inflammation, 
several important questions remain unanswered. It is unknown, 
for example, how the canonical and non-canonical pathways 
act in tandem to regulate immunity and tolerance, and how 
much crosstalk is involved with other pathways involved in the 
regulation of immune responses. Dissecting many of these issues 
around Wnt/β-catenin signaling in immune cells potentially 
helps in developing novel therapeutic strategies against various 
diseases stemming from an imbalance in the immune system.
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